GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucira Health Inc (OTCPK:LHDXQ) » Definitions » ROE %

Lucira Health (Lucira Health) ROE % : -412.63% (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Lucira Health ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Lucira Health's annualized net income for the quarter that ended in Sep. 2022 was $-507.4 Mil. Lucira Health's average Total Stockholders Equity over the quarter that ended in Sep. 2022 was $123.0 Mil. Therefore, Lucira Health's annualized ROE % for the quarter that ended in Sep. 2022 was -412.63%.

The historical rank and industry rank for Lucira Health's ROE % or its related term are showing as below:

LHDXQ's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.15
* Ranked among companies with meaningful ROE % only.

Lucira Health ROE % Historical Data

The historical data trend for Lucira Health's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucira Health ROE % Chart

Lucira Health Annual Data
Trend Dec18 Dec19 Dec20 Dec21
ROE %
- - - -102.50

Lucira Health Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -53.68 -16.33 26.59 -44.50 -412.63

Competitive Comparison of Lucira Health's ROE %

For the Medical Devices subindustry, Lucira Health's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucira Health's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucira Health's ROE % distribution charts can be found below:

* The bar in red indicates where Lucira Health's ROE % falls into.



Lucira Health ROE % Calculation

Lucira Health's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=-64.827/( (-62.308+188.803)/ 2 )
=-64.827/63.2475
=-102.50 %

Lucira Health's annualized ROE % for the quarter that ended in Sep. 2022 is calculated as

ROE %=Net Income (Q: Sep. 2022 )/( (Total Stockholders Equity (Q: Jun. 2022 )+Total Stockholders Equity (Q: Sep. 2022 ))/ count )
=-507.448/( (185.067+60.889)/ 2 )
=-507.448/122.978
=-412.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2022) net income data. ROE % is displayed in the 30-year financial page.


Lucira Health  (OTCPK:LHDXQ) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2022 )
=Net Income/Total Stockholders Equity
=-507.448/122.978
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-507.448 / 137.56)*(137.56 / 239.1105)*(239.1105 / 122.978)
=Net Margin %*Asset Turnover*Equity Multiplier
=-368.89 %*0.5753*1.9443
=ROA %*Equity Multiplier
=-212.22 %*1.9443
=-412.63 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2022 )
=Net Income/Total Stockholders Equity
=-507.448/122.978
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-507.448 / -507.392) * (-507.392 / -505.168) * (-505.168 / 137.56) * (137.56 / 239.1105) * (239.1105 / 122.978)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0001 * 1.0044 * -367.23 % * 0.5753 * 1.9443
=-412.63 %

Note: The net income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Lucira Health ROE % Related Terms

Thank you for viewing the detailed overview of Lucira Health's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucira Health (Lucira Health) Business Description

Traded in Other Exchanges
N/A
Address
1412 62nd Street, Emeryville, CA, USA, 94608
Lucira Health Inc is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. It has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fit in the palm of a hand. The company's initial focus is within respiratory diseases, and initially for COVID-19 and influenza Types A and B indications.
Executives
Anthony Joseph Allen officer: Chief Operations Officer 1412 62ND STREET, EMERYVILLE CA 94608
Epq Llc, Lcovd Safe Ps other: Less than 10% owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Chad Boeding other: CEO of 10% owner ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epiq Capital Group, Llc 10 percent owner ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epq Llc, Lcovd Ps 10 percent owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Lflu Ps other: Less than 10% owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Ltest Ps other: Less than 10% Owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Richard Clavano Narido officer: Interim CFO 12 HANSEN CT, MORAGA CA 94556
Ghazi Kashmolah officer: Ex. VP &Chief Quality Officer 1412 62ND STREET, EMERYVILLE CA 94608
Kevin Walter Collins officer: Chief Revenue Officer C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608
Dan George officer: CFO and Treasurer 1412 62ND STREET, EMERYVILLE CA 94608
Erik T. Engelson director, officer: President and Chief Executive 1412 62ND STREET, EMERYVILLE CA 94608
Debkishore Mitra director, officer: Chief Technology Officer 1412 62ND STREET, EMERYVILLE CA 94608
Tamanna Prashar officer: Vice President 1412 62ND STREET, EMERYVILLE CA 94608
Alison Mccauley director C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608